NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Electra Therapeutics, Inc. Common stock (ETRA) Stock Analysis

Electra Therapeutics, Inc. Common stock (ETRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ETRA

$9.05

+$0.24 (+2.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ETRA with… →

ETRA Key Statistics

As of Oct 21, 2026
Trading
Open
$8.89
Previous Close
$8.81
Day's Range
8.81–9.27
52-Week Range
8.50–15.50
Volume
126.06K
Valuation
Market Cap
$568.04M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.65
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$61.98M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.77M
Dividend and dates
Avg Volume
779.90K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Electra Therapeutics, Inc. Common stock (ETRA) has a market capitalization of $568.04M.

In fiscal 2025, ETRA reported revenue of $0.00.

ETRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$61.98M—
2024$0.00−$24.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$61.89M−$61.98M—
2024$0.00—−$26.32M−$24.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Electra Therapeutics, Inc. Common stock (ETRA) carries a market capitalisation of $568.04M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 46 employees.

ETRA last closed at $9.05 on October 21, 2026. That is +$0.24 (+2.72%) against the previous close. Over the past 52 weeks the price has ranged from $8.50 to $15.50. The latest close sits 6.47% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $61.98M. Earnings per share on a trailing basis come to −2.65.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for ETRA.

So far in 2026 the total return is −32.96%.

Peer Comparison

Electra Therapeutics, Inc. Common stock (ETRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Electra Therapeutics, Inc. Common stock ETRA $568.04M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Electra Therapeutics, Inc. Common stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Electra Therapeutics, Inc. Common stock

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.

Visit website →